Antibiotics maker Melinta Therapeutics, which has commercialization rights for the drug in the U.S. market, plans to make rezafungin available this summer.
https://www.pharmalive.com/wp-content/uploads/2022/05/FDA-declines-to-authorize-common-antidepressant-as-COVID-treatment-Reuters-5-16-22.jpg6281200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-03-22 18:30:152023-03-23 10:46:20Cidara gets US FDA approval for antifungal drug
